ARCHIVES

NSABP Trial Finds Raloxifene Equivalent To Tamoxifen For Cancer Risk Reduction

This article is from The Cancer Letter archive.

Vol. 29 No. 4 | April 28, 2006

Download PDF Visit The Full Archive

Related Articles

Varmus’s 2016 Bypass Budget Seeks “Modest” Increase of $823 Million

December 5, 2014

In Brief: James Downing named CEO of St. Jude

June 27, 2014

Cooperative Groups: Committee Formed To Implement Armitage Report Had A Rough Start

June 12, 1998

DCE Board Approves concept For New Studies On Black, White Differences In Cancer Rates

July 13, 1984

CTEP Drafts FDA Approval Guidelines

March 4, 1988

DCPC Bard Approves Concepts For New Grant Programs

November 13, 1992